{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:33:57Z","timestamp":1790004837503,"version":"4.0.1"},"reference-count":40,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,10,14]],"date-time":"2016-10-14T00:00:00Z","timestamp":1476403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2017,1]]},"abstract":"\n Aim<\/jats:title>\n To examine the lipid and glycaemic effects of 52 weeks of treatment with evolocumab.<\/jats:p>\n <\/jats:sec>\n \n \n Materials and\n M<\/jats:styled-content>\n ethods\n <\/jats:title>\n \n The\n D<\/jats:styled-content>\n urable\n E<\/jats:styled-content>\n ffect of\n PCSK9 A<\/jats:styled-content>\n ntibody\n C<\/jats:styled-content>\n ompared with\n P<\/jats:styled-content>\n lacebo\n S<\/jats:styled-content>\n tudy (\n DESCARTES<\/jats:styled-content>\n ) was a 52\u2010week placebo\u2010controlled trial of evolocumab that randomized 905 patients from 88 study centres in 9 countries, with 901 receiving at least one dose of study drug. For this post\u2010hoc analysis,\n DESCARTES<\/jats:styled-content>\n patients were categorized by baseline glycaemic status: type 2 diabetes, impaired fasting glucose (\n IFG<\/jats:styled-content>\n ), metabolic syndrome (\n MetS<\/jats:styled-content>\n ) or none of these. Monthly subcutaneous evolocumab (420 mg) or placebo was administered. The main outcomes measured were percentage change in\n LDL<\/jats:styled-content>\n \u2010cholesterol (\n LDL\u2010C<\/jats:styled-content>\n ) at week 52 and safety.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 413 patients had dysglycaemia (120, type 2 diabetes; 293,\n IFG<\/jats:styled-content>\n ), 289 had\n MetS<\/jats:styled-content>\n (194 also had\n IFG<\/jats:styled-content>\n ) and 393 had none of these conditions. At week 52, evolocumab reduced\n LDL\u2010C<\/jats:styled-content>\n by >50% in all subgroups, with favourable effects on other lipids. No significant differences in fasting plasma glucose,\n HbA1c<\/jats:styled-content>\n , insulin,\n C<\/jats:styled-content>\n \u2010peptide or\n HOMA<\/jats:styled-content>\n indices were seen in any subgroup between evolocumab and placebo at week 52. The overall incidence of new\u2010onset diabetes mellitus did not differ between placebo (6.6%) and evolocumab (5.6%); in those with baseline normoglycaemia, the incidences were 1.9% and 2.7%, respectively. Incidences of\n AEs<\/jats:styled-content>\n were similar in evolocumab\u2010 and placebo\u2010treated patients.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Evolocumab showed encouraging safety and efficacy at 52 weeks in patients with or without dysglycaemia or\n MetS<\/jats:styled-content>\n . Changes in glycaemic parameters did not differ between evolocumab\u2010 and placebo\u2010treated patients within the glycaemic subgroups examined.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.12788","type":"journal-article","created":{"date-parts":[[2016,9,13]],"date-time":"2016-09-13T03:13:36Z","timestamp":1473736416000},"page":"98-107","source":"Crossref","is-referenced-by-count":58,"title":["Evaluation of the efficacy, safety and glycaemic effects of evolocumab (\n AMG<\/scp>\n 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome"],"prefix":"10.1111","volume":"19","author":[{"given":"Dirk J.","family":"Blom","sequence":"first","affiliation":[{"name":"Division of Lipidology, Department of Medicine University of Cape Town, Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Koren","sequence":"additional","affiliation":[{"name":"Jacksonville Center for Clinical Research Jacksonville Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Roth","sequence":"additional","affiliation":[{"name":"Sterling Research Group Cincinnati Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Monsalvo","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Stephen","family":"Djedjos","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Fremont California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patric","family":"Nelson","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals San Diego California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Elliott","sequence":"additional","affiliation":[{"name":"Amgen Limited Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Wasserman","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine Houston Texas"},{"name":"Houston Methodist DeBakey Heart and Vascular Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rury R.","family":"Holman","sequence":"additional","affiliation":[{"name":"Diabetes Trials Unit OCDEM, University of Oxford Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,10,14]]},"reference":[{"key":"e_1_2_6_2_1","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2015"},{"key":"e_1_2_6_3_1","volume-title":"Global Atlas on Cardiovascular Disease Prevention and Control","year":"2011"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.3.848"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60484-9"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60040-4"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3260-6"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16895-5"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc05-2465"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr158"},{"key":"e_1_2_6_12_1","first-page":"S1","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone NJ","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-7-201304020-00004"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv043"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2008.02062.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2215"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.10.053"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61965-6"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.860"},{"key":"e_1_2_6_20_1","doi-asserted-by":"crossref","unstructured":"Barkas F. Elisaf M. Liberopoulos E. Klouras E. Liamis G. Rizos E.C.Statin therapy with or without ezetimibe and the progression to diabetes. J. Clin. Lipidol. 2016;10(2):306\u2013313.","DOI":"10.1016\/j.jacl.2015.11.015"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-015-0036-z"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep13823"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.09.036"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-006-0269-5"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2015.194"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.1206"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2006.12.008"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0b013e3283587563"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2014.902929"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316222"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.169404"},{"key":"e_1_2_6_32_1","unstructured":"Diabetes Trials Unit. HOMA2 calculator. Available at:www.dtu.ox.ac.uk\/homacalculator\/. The Oxford Centre for Diabetes Endocrinology and Metabolism. Accessed on 8 May 2016."},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)00003-6"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.801"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000131"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902604"},{"issue":"1","key":"e_1_2_6_37_1","first-page":"S79","article-title":"Evaluation of the one\u2010year efficacy, safety and glycaemic effects of evolocumab (AMG 145) in 4,802 subjects with, at high risk for, or at low risk for, diabetes mellitus","volume":"58","author":"Sattar N","year":"2015","journal-title":"Diabetologia"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501031"},{"issue":"43","key":"e_1_2_6_39_1","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein JJ","year":"2015","journal-title":"Eur Heart J"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.01.079"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2015.11.015"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12788","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12788","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12788","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:54:02Z","timestamp":1761868442000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,14]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1111\/dom.12788"],"URL":"https:\/\/doi.org\/10.1111\/dom.12788","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,14]]}}}